Haemonetics Corporation (HAE) Stock Is An All-Time High Flier

March 14, 2018 - By Richard Conner

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.42, from 1.7 in 2017Q2. It fall, as 16 investors sold Haemonetics Corporation shares while 60 reduced holdings. 33 funds opened positions while 64 raised stakes. 52.55 million shares or 2.13% less from 53.69 million shares in 2017Q2 were reported.
Gemmer Asset Management Ltd Company invested 0% in Haemonetics Corporation (NYSE:HAE). Pitcairn holds 0.03% or 6,092 shares in its portfolio. Menta Cap Limited Liability Corporation holds 0.18% or 27,625 shares in its portfolio. Federated Invsts Pa holds 0% or 1,197 shares in its portfolio. State Teachers Retirement Systems, New York-based fund reported 101,326 shares. Fisher Asset Limited Liability Co owns 243,275 shares. Connor Clark Lunn Limited accumulated 5,925 shares. Meeder Asset Management stated it has 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). First Quadrant Lp Ca holds 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 8,889 shares. Pacad Inv holds 0.02% in Haemonetics Corporation (NYSE:HAE) or 1,900 shares. Amp Capital Invsts invested 0% in Haemonetics Corporation (NYSE:HAE). Acadian Asset Mngmt Ltd Liability Corporation invested 0.05% in Haemonetics Corporation (NYSE:HAE). California State Teachers Retirement Systems reported 83,898 shares. Texas Permanent School Fund has invested 0.02% in Haemonetics Corporation (NYSE:HAE). Retail Bank Of America De has 0.01% invested in Haemonetics Corporation (NYSE:HAE).

Since January 2, 2018, it had 0 insider buys, and 3 sales for $484,765 activity. On Tuesday, January 2 the insider KROLL MARK W sold $448,434. Another trade for 389 shares valued at $28,097 was made by Basil Michelle L on Tuesday, March 6.

The stock of Haemonetics Corporation (NYSE:HAE) reached all time high today, Mar, 14 and still has $80.58 target or 8.00 % above today’s $74.61 share price. This indicates more upside for the $3.99 billion company. This technical setup was reported by Barchart.com. If the $80.58 PT is reached, the company will be worth $319.04M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.27% or $0.2 during the last trading session, reaching $74.61. About 218,019 shares traded. Haemonetics Corporation (NYSE:HAE) has risen 45.56% since March 14, 2017 and is uptrending. It has outperformed by 28.86% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 14. They expect $0.43 earnings per share, up 10.26 % or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.98 million for 43.38 P/E if the $0.43 EPS becomes a reality. After $0.62 actual earnings per share reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65 % negative EPS growth.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 10 analysts covering Haemonetics Corporation (NYSE:HAE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Haemonetics Corporation had 27 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, February 7. Jefferies maintained Haemonetics Corporation (NYSE:HAE) on Tuesday, June 20 with “Buy” rating. The rating was maintained by Craig Hallum with “Hold” on Wednesday, November 8. Benchmark maintained the shares of HAE in report on Monday, November 7 with “Hold” rating. The stock of Haemonetics Corporation (NYSE:HAE) has “Neutral” rating given on Monday, August 15 by Sidoti. On Tuesday, February 7 the stock rating was downgraded by Barrington Research to “Mkt Perform”. Benchmark maintained it with “Hold” rating and $35 target in Thursday, November 5 report. The rating was maintained by Jefferies on Tuesday, August 2 with “Buy”. Barrington Research upgraded Haemonetics Corporation (NYSE:HAE) rating on Tuesday, July 28. Barrington Research has “Outperform” rating and $43 target. The firm earned “Hold” rating on Wednesday, May 11 by Benchmark.

Another recent and important Haemonetics Corporation (NYSE:HAE) news was published by Zacks.com which published an article titled: “Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?” on March 08, 2018.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $3.99 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: